Mark J. Ratain to Drug Monitoring
This is a "connection" page, showing publications Mark J. Ratain has written about Drug Monitoring.
Connection Strength
1.778
-
Therapeutic Drug Monitoring of Oral Oncology Drugs: Another Example of Maslow's Hammer. Clin Pharmacol Ther. 2024 Sep; 116(3):508-510.
Score: 0.878
-
Intraindividual Pharmacokinetic Variability: Focus on Small-Molecule Kinase Inhibitors. Clin Pharmacol Ther. 2018 06; 103(6):956-958.
Score: 0.565
-
Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring. Cancer Surv. 1993; 17:51-78.
Score: 0.100
-
Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide. Clin Pharmacol Ther. 2002 Dec; 72(6):638-47.
Score: 0.050
-
A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer. Cancer Chemother Pharmacol. 2002 Jul; 50(1):1-5.
Score: 0.048
-
The Right Dose: From Phase I to Clinical Practice. Am Soc Clin Oncol Educ Book. 2021 Mar; 41:92-106.
Score: 0.044
-
COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia. Clin Pharmacol Ther. 2021 03; 109(3):688-696.
Score: 0.044
-
Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. J Clin Oncol. 1995 Sep; 13(9):2196-207.
Score: 0.030
-
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Invest New Drugs. 2008 Jun; 26(3):233-9.
Score: 0.018